ABBOTT LABORATORIES overview

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT PR Newswire NEW YORK, June 27, 2022 NEW YORK , June 27, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Abbott and certain of its officers and/or...

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, reminds investors it is investigating whether certain directors and officers of Abbott Laboratories (“Abbott”) (NYSE: ABT) breached their fiduciary duties to Abbott and its shareholders. If you are an Abbott shareholder, you are encouraged to contact attorney Joe Pettigrew with Scott+Scott for additional information at (844) 818-6982 or jpettigrew@scott-scott.com . Scott+Scott is...

Texas Gov. Greg Abbott holds a press conference to provide an update on the state's border security mission. #foxbusiness ......

Fox News contributor Joe Concha comments on the White House doubling down on false narratives surrounding inflation, ......

New scrutiny arises around the conditions of an Abbott Nutrition baby formula plant before the closure in February that ......

Abbott Declares 394th Consecutive Quarterly Dividend PR Newswire ABBOTT PARK, Ill., June 10, 2022 ABBOTT PARK , Ill. , June 10, 2022 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 47 cents per share. This marks the 394 th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2022, to shareholders of record at the close of business on July 15, 2022 . Abbott has increased its dividend payout...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT PR Newswire NEW YORK, June 8, 2022 NEW YORK , June 8, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Abbott and certain of its officers and/or...

Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System PR Newswire ABBOTT PARK, Ill., June 3, 2022 Abbott is designing a first-of-its-kind biowearable that will enable people with diabetes to continuously monitor glucose and ketones in one sensor Device promises to redefine care for people with diabetes who are at risk for developing a life-threatening complication called diabetic ketoacidosis ABBOTT PARK , Ill. , June 3, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today...